Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Health, to discuss the clinical promise of psychedelics and what’s next for psychiatric innovation. What you’ll learn: What’s driving the momentum behind psilocybin therapy Why i...
All content for The Syneos Health Podcast is the property of Syneos Health and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Health, to discuss the clinical promise of psychedelics and what’s next for psychiatric innovation. What you’ll learn: What’s driving the momentum behind psilocybin therapy Why i...
As regulatory expectations evolve under the FDA’s Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach. In this fourth episode of our Project Optimus series, host Dr. Wael Harb is joined by biostatistics expert X.Q Xue, PhD, Vice President and Global Head, Biostatistics at Syneos Health to explore how statistical science is transforming dose optimizatio...
The Syneos Health Podcast
Now in its second season, this exclusive CNS Summit podcast series features biopharma leaders sharing bold ideas, breakthrough innovations and what it takes to move smarter and faster for patients. Compass Pathways CEO Kabir Nath joins host, Dr. Alex Wise, Global Head of Neuroscience at Syneos Health, to discuss the clinical promise of psychedelics and what’s next for psychiatric innovation. What you’ll learn: What’s driving the momentum behind psilocybin therapy Why i...
